The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Smoking Cessation Halves MACE Risk, Reduction Offers Little Protection
Patients with stable CAD who quit smoking reduced the risk of a major event by nearly 50%, while a reduction in smoking habits demonstrated minimal effects.
ESC Congress 2024 Lipidology Preview, with Professor Kausik Ray
Kausik Ray, MD, discusses what trials and new data in lipidology he is most looking forward to from the upcoming ESC Congress.
Diabetes Dialogue: Sotagliflozin for T1D and Other ADCES 2024 Highlights
This episode focuses on sotagliflozin in type 1 diabetes and other highlights from the ADCES 2024 annual meeting.
Laurence Sperling, MD: Navigating the Changing Landscape of Lipidology
Laurence Sperling, MD, offers perspective on multiple topics within the evolving field of lipid management and dyslipidemia.
Diabetes Dialogue: Navigating ADCES 2024
The first of 2 episodes on ADCES 2024, this episode focuses on sessions and presentations hosts Isaacs and Bellini participated in during the meeting.
ESC Congress 2024 Clinical Trials to Watch, with Deepak Bhatt, MD, MPH, MBA
Deepak Bhatt, MD, MPH, MBA, discusses 7 trials to watch from hotline or late-breaking sessions at the upcoming European Society of Cardiology Congress 2024.
Previewing the Family Heart Global Summit, with Laurence Sperling, MD
Laurence Sperling, MD, provides an overview of the Family Heart Global Summit, including previewing the meeting and discussing where interested attendees can learn more.
Brett King, MD, PhD: Value of LEVEL UP Data and Pushing New Standards in Dermatology
Brett King, MD, PhD, discusses the LEVEL UP trial and how it represents the field of dermatology's desire to advance care and advocate for new standards of care.
Sickle Cell Disease Linked to Higher Risk of Retinal Vascular Occlusion
Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.
Fathers with Type 1 Diabetes May Be More Likely to Pass on Disease than Mothers
An analysis of more than 11,000 people with T1D found people were more likely to report an affected father than an affected mother.
Study Links DOACs to Reduction in RVO, Intraocular Bleeding Risk
A first-time comparison in US patients displays the protective association of DOACs over warfarin use on RVO and intraocular bleeding risk.
Teleretinal Screening Motivates Sickle Cell Patients to Seek Eye Care
A teleretinal screening program improved the awareness of sickle cell retinopathy and motivated patients to visit an eye care provider.
Age Influences Anti-VEGF Effectiveness in DME Treatment
Older patient age was linked to suboptimal anti-VEGF response for diabetic macular edema in DRCR clinical trials.
Macular Atrophy Progresses Similarly in Wet and Dry AMD Types
Geographic atrophy in eyes with dry AMD and macular atrophy in fellow eyes with neovascular AMD demonstrate similar growth rates.
HCPLive Five at ASRS 2024
Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key interviews from the American Society of Retina Specialists (ASRS) 42nd Annual Meeting.
Jordana Fein, MD: Pre-Dose IOP Outcomes After Aflibercept 8 mg for DME
Pre-dose IOP outcomes in eyes with DME receiving aflibercept 8 mg or 2 mg were comparable through Week 48 of the Phase 2/3 PHOTON trial.
Diana Do, MD: Impact of Baseline BCVA on Aflibercept 8 mg Outcomes in DME
A post hoc analysis of PHOTON showed the utility of aflibercept 8 mg in patients with DME, irrespective of baseline visual acuity.
Top Gene Therapy News at ASRS 2024
A recap of the 5 most popular topics related to gene therapy in ophthalmology coming from the 42nd American Society of Retina Specialists meeting.
Ophthalmologists, Patients Hesitate to Switch to Anti-VEGF Biosimilars
Hesitancy with anti-VEGF biosimilars was identified in a survey among both ophthalmologists and patients with nAMD in Canada.
Capability of ChatGPT Reduced in Complex Vitreoretinal Scenarios
Across 40 clinical scenarios, ChatGPT did not provide a comprehensive response in 50% of clinical questions with nearly 30% hallucinated sources.
Male Sex, Younger Age Linked to Sickle Cell Retinopathy Progression
Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.
Sozinibercept Combination Therapy Exhibits Durability for nAMD, DME
Intravitreal dosing of sozinibercept up to 2 mg in combination with ranibizumab or aflibercept was well tolerated and supported ≥Q8W dosing intervals.
Semaglutide May Reduce Rates of Diabetic Retinopathy Outcomes
A database analysis linked semaglutide use to notable reductions in the rates of diabetic macular edema and vitreous hemorrhage in diabetic retinopathy.
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X
Presented at ASRS 2024, late-breaking RHONE-X data shows more than 90% of patients experienced the absence of DME after four years of faricimab.
FDA Accepts sBLA for Susvimo in Treatment of DME, Diabetic Retinopathy
The FDA accepted Genentech’s supplemental BLA for Susvimo, based on the one-year results from the Phase III Pagoda and Pavilion studies.
Dilraj Grewal, MD: Development of MNV in Geographic Atrophy in GATHER Trials
Eyes with GA that developed MNV in the GATHER trials experienced a slower growth rate with avaincaptad pegol than with sham treatment.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy
Patients treated with PDS with ranibizumab refilled every nine months maintained vision improvements and experienced consistent safety over two years.
Study Links Maternal Asthma to Blinding Eye Disease in Premature Infants
New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.
Once-Daily Gildeuretinol Acetate Could Halt Progression of Early Stargardt Disease
New data from the TEASE-3 trial presented at the ASRS meeting shows gildeuretinol acetate may blunt disease progression in early-stage Stargardt disease patients.
Carl C. Awh, MD: Two-Year Outcomes of the Port Delivery System for DME
Over 2 years, the Port Delivery System demonstrated continued efficacy with fixed refill-exchange procedures every 24 weeks in the Phase 3 Pagoda trial.